From JPMA Holding of the "Pharmaceutical Manufacturers Association of Japan (PMAJ) Press Conference on the Establishment of an Action Fund for AMR (Antimicrobial Resistance)
The event to establish the "Drug Resistance (AMR) Action Fund," a groundbreaking partnership aimed at providing patients with two to four new antibiotics by 2030, was held on July 10, 2020 in the form of a press conference hosted by the Pharmaceutical Manufacturers Association of Japan (PMAJ) at Hotel Metropolitan Edmont (Tokyo, Japan) Chiyoda-ku, Tokyo) on July 10, 2020, in the form of a press conference hosted by the Pharmaceutical Manufacturers Association of Japan. In addition to the background and purpose of the AMR Action Fund, leading figures from industry, academia, and government provided information on the lessons we are learning from the global spread of COVID-19 and the need to prepare for new infectious disease outbreaks that may occur in the future. Leading experts from industry, academia, and government provided information on what we are learning from the global spread of infectious diseases and the need to prepare in parallel for possible future outbreaks.
The AMR Action Fund, established by more than 20 global biopharmaceutical companies, will raise nearly US$1 billion to support research and development of innovative new antibiotics to combat the most resistant bacteria and life-threatening infectious diseases. The fund has been endorsed by the World Health Organization (WHO), the European Investment Bank (EIB), and the Wellcome Trust Foundation.
The series of events, led by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in collaboration with national and regional industry associations, was held simultaneously in Washington, D.C., USA and Berlin, Germany, on July 9, 2020, and was broadcast live worldwide via the Internet. The event was broadcast live worldwide via the Internet. The press conference in Japan was also streamed live, and was viewed by many people, including media representatives who attended the press conference.
(From the July 10 Pharmaceutical Manufacturers Association of Japan press conference "Lessons Learned from the Spread of the New Coronavirus and Preparations for Drug Resistance (AMR)")
Japan Pharmaceutical Manufacturers Association
Chairman Joji Nakayama
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
The Pharmaceutical Manufacturers Association of Japan (PMAJ), founded in 1968, is an association of R&D-oriented pharmaceutical companies that aim to contribute to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
The organization is dedicated to promoting a deeper understanding of pharmaceuticals and providing policy recommendations for the sound development of the pharmaceutical industry, with the aim of realizing patient-participatory medicine.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers Association of Japan (PAPJ) is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association
